Diamyd Medical AB (publ) Logo

Diamyd Medical AB (publ)

Developing precision immunotherapies to preserve insulin in autoimmune diabetes.

DMYD | ST

Overview

Corporate Details

ISIN(s):
SE0005162872 (+5 more)
LEI:
5493003NP2HNQDEKB804
Country:
Sweden
Address:
BOX 7349, 103 90 STOCKHOLM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Diamyd Medical AB is a clinical-stage company developing precision medicine therapies to prevent and treat autoimmune diabetes, primarily Type 1 Diabetes and Latent Autoimmune Diabetes in Adults (LADA). Its lead product candidate, Diamyd®, is an antigen-specific immunotherapy designed to preserve the body's own insulin-producing capabilities. The therapy, administered intralymphatically, targets individuals with a specific HLA genotype. Diamyd® is undergoing evaluation in the pivotal Phase 3 trial, DIAGNODE-3, and the Phase 2 prevention trial, DiaPrecise. The company is also establishing a facility for the manufacturing of its biological active ingredient, GAD65.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Diamyd Medical AB (publ) and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Diamyd Medical AB (publ) filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Diamyd Medical AB (publ) via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.